Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(11)
•••
Comment by pattyb77on Apr 11, 2019 6:44pm
83 Views
Post# 29615865

RE:RE:RE:RE:RE:RE:RE:almost 10 million on the bid!

RE:RE:RE:RE:RE:RE:RE:almost 10 million on the bid!
alejo.g3ologist wrote:
pattyb77 wrote:
serendipidy wrote: When the bid is higher than the ask the price will go up, seriously wtf????


When the bid volume is higher than the ask volume, the selling is stronger, and the price is more likely to move down than up. When the ask volume is higher than the bid volume, the buying is stronger, and the price is more likely to move up than down.


This shouldn't really matter if u r long term investor..these are minuscules things to be honest, maybe some ppl should go back to high school economy supply and demand class! The more ppl want in to buy(bid volume higher than ask volume) the stronger sp gets moving up in the long term..if ppl sell (big ask volume) obviously s.p declines in the near term..simple patty ;) if u r a day trader please get that figured out before losing it all ;)


I copy and pasted my last post from a website, im fairly familiar with how it works as I do alot of day trading. I also understand how unimportant it is for long term investors (only use for it is to see outside investor interest, really...) Im long on KALY regardless, Ive kinda stopped looking at this board recently because I rarely look at the SP of KALY anymore.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities